Tvardi Therapeutics reports phase one clinical trial data

• Tvardi reported Phase 1 data for TTI-109, a phosphate prodrug of STAT3 inhibitor TTI-101.
• TTI-109 showed near-identical exposure to TTI-101 at molar-equivalent doses and shorter diarrhea duration.
• The company said it plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to funding and IND clearance.

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 data for TTI-109, a phosphate prodrug of STAT3 inhibitor TTI-101, including up to 60% reductions in STAT3-driven Th17, Tfh, and B cell populations.

The update follows earlier company guidance that topline TTI-109 healthy volunteer data and a clinical development strategy were expected in 2026.

Tvardi said TTI-109 showed rapid conversion to TTI-101, near-identical exposure at molar-equivalent doses, and stable 21-day pharmacokinetics.

The company also reported shorter diarrhea duration with TTI-109 than TTI-101, at 0.46 days compared with 3.35 days.

Following the announcement the Tvardi Therapeutics share price was up at $2.01.

Tvardi said it plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding and IND clearance.

Recent company updates have focused on TTI-109, TTI-101, STAT3-driven disease programs, hepatocellular carcinoma data expected in 2026, and cash runway into Q4 2026.